Kisqali (ribociclib) — United Healthcare
Advanced, recurrent, or metastatic breast cancer
Preferred products
- anastrozole
- letrozole
- exemestane
- Faslodex (fulvestrant)
Initial criteria
- Diagnosis of advanced, recurrent, or metastatic breast cancer
- AND Disease is hormone receptor (HR)-positive
- AND Disease is human epidermal growth factor receptor 2 (HER2)-negative
- AND One of the following:
- Used in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) OR Used in combination with Faslodex (fulvestrant)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Kisqali therapy
Approval duration
12 months